@‘Sl“Iˆã—ÊJ”ŠwuÀ@—Õ°ŒŸ¸ˆãŠw•ª–ì
@@@
Department of Laboratory Medicine
@•ª–ì’·‚Ì’è”N‘ÞE‚ª‹ß‚¢‚½‚ßA‘åŠw‰@¶‚ÌV‹KŽó‚¯“ü‚ê‚Í’âŽ~‚µ‚Ü‚µ‚½
y“–Œ¤‹†Žº‚ÌŒ¤‹†ƒe[ƒ}z
ƒe[ƒ} 1F@”’ŒŒ•aEƒŠƒ“ƒpŽî×–E‚̈Ùí‘B‚Ì×–E•ªŽq¶•¨Šw“IƒƒJƒjƒYƒ€‚̉ð–¾B“Á‚ÉA‹}«”’ŒŒ•aвזE‚̧ŒäƒVƒOƒiƒ‹‚̉ð–¾
@@@@@
@@ˆÓ‹`:@’P‚ÉA޾г–¼‚â•aŒ^‚Ìf’f‚ð‚·‚é‚̂ł͂ȂAŠeǗႲ‚Ƃ̔ǂâ‘B‚ÌŒ®‚ƂȂ镪Žq•a‘Ԃ𖾂炩‚É‚·‚éŒÂ«f’f–@‚ðŠJ”‚·‚éB
@@@@@@@@@@ ”’ŒŒ•a×–E‘S‘̂ł͂ȂA”’ŒŒ•aвזE‚ðŽ¡—Ã•W“I‚Æ‚·‚邱‚Æ‚ÅAŽîᇂ̗}§‚ł͂ȂAªâ‚ð–ÚŽw‚·Ž¡—ÂɌq‚ªé•ªŽq•a‘Ô‚ð‰ð–¾‚·‚éB
ƒe[ƒ} 2F@ã‹L‚Ì•ªŽqƒƒJƒjƒYƒ€‚ɑ΂·‚éV‹K•ªŽq•W“I–ò‚Ì’Tõ‚ÆA—LŒø«‚ð—\‘ª‚·‚é–òÜŠ´Žó«ŒŸ¸–@‚ÌŠJ”
@@ˆÓ‹`F ]—ˆŒ^‚ÌR‚ª‚ñ܂ͳí×–E‚ðŠª‚«ž‚ñ‚Å×–E‚ð‰ó‚µ‚Ä‚µ‚Ü‚¤‚½‚ßAŽîá‡×–E‚¾‚¯‚ð‰ó‚·•ªŽq•W“I–ò‚ª–]‚Ü‚ê‚éB
@@@@@ Œ»ÝAŽíX‚Ì•ªŽq•W“I–ò‚ª—Õ°‰ž—p‚³‚ê‚Ä‚¢‚邪A—LŒø«‚ð—\‘ª‚·‚錟¸‚Í\•ª‚ɂͮ‚Á‚Ä‚¢‚È‚¢‚½‚ßA‚»‚ê‚ðŠJ”‚·‚éB
@@@@@ ‚³‚ç‚ÉA»–òŠé‹Æ‚âŠCŠOŒ¤‹†Ž{݂̑n–òŒ¤‹†ŽÒ‚Æ‹¤“¯‚ÅAV‚½‚È•ªŽq•W“I–ò‚Ì•W“I‚ƂȂ镪Žq‚ð’Tõ‚·‚éB
ƒe[ƒ}3F@ŽîᇂÌV‚½‚Ȉâ“`ŽqŒŸ¸–@‚â”÷—ÊŽc‘¶Žîá‡×–E‚ÌŒŸo–@‚ÌŠJ”
@@@@@
@@ˆÓ‹`: ‹ß”NAŒ¤‹†ŽºƒŒƒxƒ‹‚ÅŽîᇂ̗lX‚Ȉâ“`ŽqˆÙ킪Œ©‚¢o‚³‚ê‚Ä‚¢‚邪A—Õ°Œ»ê‚ʼnž—p‚Å‚«‚邿‚¤‚ÈŠÈ•Ö‚Å‚Š´“x‚Ȉâ“`ŽqŒŸ¸–@‚ðŠJ”‚·‚éB
@@@@@@@@@ Žîá‡×–E‚©‚ç—Vo‚µ‚ÄŒŒ‰t’†‚𗬂ê‚éˆâ“`Žq’f•ЂðŒŸo‚·‚éAгŽÒ‚³‚ñ‚ւ̶ŒŸ‚ÌNP‚ð—v‚³‚È‚¢ˆâ“`ŽqŒŸ¸–@‚ðŠJ”‚·‚éB
@@@@@iÅ‹ßA‚±‚ÌŽè–@‚ÍuƒŠƒLƒbƒhƒoƒCƒIƒvƒV[v‚Æ‚µ‚Ä¢ŠE‚Řb‘è‚ɂȂÁ‚Ä‚¢‚Ü‚·‚ªA“–ƒ‰ƒ{‚Å‚Í17”N‘O‚©‚çŽÀŽ{‚µ‚Ä‚¢‚Ü‚·j
‚±‚̂ق©AŒŸ¸•”׋یŸ¸Žº‚ÅA‰@“àŠ´õŠÄŽ‹‚Ì‚½‚ß‚Ì׋ۂ̈â“`ŽqŒ^‰ð͂⓯’è‚ÌŒŸ¸–@‚ðŠJ”‚µ‚Ä‚¢‚Ü‚·B
ˆêlˆêl‚ª“Æ—§‚µ‚½ƒe[ƒ}‚ÅŒ¤‹†‚ð‚µ‚Ä‚¢‚Ü‚·B@¨
ƒe[ƒ}‚ªŒ©‚‚©‚ç‚È‚¯‚ê‚Î’ñ‹Ÿ‚µ‚Ü‚·B
•¡”‚̃e[ƒ}‚ð•Às‚µ‚Äs‚¤‚±‚Æ‚à‰Â”\‚Å‚·B@@¨
Œ¤‹†‚Ì•‚ðŠg‚°‚邽‚ßA‚¨‚æ‚ÑAˆê‚‚ª‚¤‚Ü‚‚¢‚©‚È‚©‚Á‚½Žž‚Ì”õ‚¦‚Æ‚µ‚ÄB
Eê‚ÌðŒ‚ª‹–‚¹‚ÎAŽÐ‰ïl‘åŠw‰@¶‚à‰Â”\‚Å‚·B¨
“‚«‚È‚ª‚çŠwˆÊŽæ“¾‚à–ÚŽw‚·ƒVƒXƒeƒ€‚Å‚·B
y“–Œ¤‹†Žº‚ÅC“¾‚Å‚«‚錤‹†Žè–@z
‘åŠw‰@¶‚ªC“¾‚·‚錤‹†Žè–@‚Æ‚µ‚ÄA×–E”|—{A×–EŒ`‘ÔŠÏŽ@Aƒtƒ[ƒTƒCƒgƒƒgƒŠ[‰ðÍAPCR‚ð—p‚¢‚½DNA•ψىðÍA’è—ÊRT-PCRAƒCƒ€ƒmƒuƒƒbƒg‰ð͂Ȃǂðs‚¤B
•K—v‚ɉž‚¶‚ÄAƒRƒƒj[ƒAƒbƒZƒCAŒuŒõŒ°”÷‹¾‚É‚æ‚é×–E“à’`”’‰ðÍAƒV[ƒNƒGƒ“ƒX‰ðÍAsiRNA“±“üiƒGƒŒƒNƒgƒƒ|ƒŒ[ƒVƒ‡ƒ“–@jAƒ}ƒCƒNƒƒAƒŒƒC‚É‚æ‚é–Ô—…“Iˆâ“`Žq”Œ»‰ðÍAŽŸ¢‘ãƒV[ƒNƒGƒ“ƒT[‚É‚æ‚éƒGƒNƒ\[ƒ€‰ðÍ‚âRNA-seq‰ðÍ‚ðs‚¤B
‚±‚ê‚ç‚ÌÝ”õ‚̓‰ƒ{“à‚É®‚Á‚Ä‚¢‚邪Aƒ}ƒCƒNƒƒAƒŒƒC‰ð͂ƎŸ¢‘ãƒV[ƒNƒGƒ“ƒT[‚Í‹¤“¯Œ¤‹†Ž{Ý‚âŠO•”ˆÏ‘õ‚Ås‚¤B
ŽÀŒ±‚ÌŒoŒ±‚ª‘S‚‚È‚‚Ä‚à–â‘è‚Í‚ ‚è‚Ü‚¹‚ñB‘åŠw‰@“üŠw‘O‚ÍŒoŒ±‚ª‚È‚¢‚Ì‚ª•’ʂł·B“–ƒ‰ƒ{‚ÅŽè‹Z‚ðŽw“±‚µ‚Ü‚·B
y‘åŠw‰@¶‚Ì–Ú•Wz
@
1jŽÀŒ±‚⌤‹†¶Šˆ‚ðŠy‚µ‚Þ‚±‚Æ‚ª‚Å‚«AV‚½‚È”Œ©‚ÉŠì‚Ñ‚ðŠ´‚¶‚邱‚Æ‚ª‚Å‚«‚éƒTƒCƒGƒ“ƒeƒBƒXƒg‚ɂȂéB
@i«—ˆAŒ¤‹†ŽÒ‚ɂȂç‚È‚¢‚Æ‚µ‚Ä‚àA‚»‚ꂼ‚ê‚ÌŽdŽ–‚ÅA‰ÈŠw“I‚ÈŽvl—͂┻’f—Í‚ª–ð‚É—§‚¿‚Ü‚·j
2j•M“ª‰‰ŽÒ‚Æ‚µ‚Ä‘“àŠw‰ï‚ÅŒ¤‹†¬‰Ê‚ð”•\‚·‚éB
@ Šwp“I‚ɈӋ`[‚¢¬‰Ê‚ª“¾‚ç‚ꂽꇂÍi‚Æ‚¢‚¤‚©A‰‰‘肪ƒAƒNƒZƒvƒg‚³‚ꂽ‚çj‘ÛŠw‰ï‚Å”•\‚·‚éB
@i—·”ï‚Í‹³Žº‚Å•‰’S‚µ‚Ä‚¢‚Ü‚·j
3j‚±‚ê‚ç‚̬‰Ê‚ÍA•M“ª’˜ŽÒ‚Æ‚µ‚ÄA‰p•¶Œ´’˜˜_•¶‚É‚·‚éB
@i‹³ˆõ‚ª˜_•¶ì¬‚̃Tƒ|[ƒg‚ð‚µ‚Ü‚·j
y“–Œ¤‹†Žº‚Ì“ú‰Ûz
@
‘Sˆõ‚Ås‚¤Œ¤‹†”•\ƒ~[ƒeƒBƒ“ƒOAŠw‰ï—\‰‰‰ï‚âŽG—p‚ÌŽžŠÔˆÈŠO‚É‚ÍA“Á‚ÉŒˆ‚Ü‚è‚͂ȂAD‚«‚ÈŽž‚É—ˆ‚ÄŽÀŒ±‚ðŠJŽn‚µAI—¹‚µ‚ÄŒ‹\‚Å‚·B
ŠwŠO‚ł̃Aƒ‹ƒoƒCƒg‚à‰Â”\‚Å‚·BŠó–]‚ª‚ ‚ê‚ÎAƒeƒB[ƒ`ƒ“ƒOEƒAƒVƒXƒ^ƒ“ƒgi—L‹‹j‚Æ‚µ‚ÄAˆãŠw‰ÈŽÀK‚ÌŽè“`‚¢‚ðs‚¢‚Ü‚·B
y˜A—æz
“Œ“ci‚Æ‚¤‚¾j@tohda.mlab@tmd.ac.jp@@ 03-5803-5334i’¼’Êj
Œ¤‹†ƒe[ƒ}‚ÍAŽîᇂ̑B‹@˜‚̉𖾂₻‚Ì•ªŽq•W“IŽ¡—Öò‚ÌŠ´Žó«ŽŽŒ±AV‚½‚Ȉâ“`ŽqŒŸ¸–@‚ÌŠJ”‚Ȃǂª’†S‚ƂȂè‚Ü‚·‚ªAŠeŽ©‚ÌŠó–]‚â«—ˆ‚Ìi˜H‚ÉŠî‚¢‚đВk‚ÌãA‰Â”\‚ÈŒÀ‚艞‚¶‚邿‚¤‚É‚µ‚Ü‚·B‚È‚¨A󋵂̕ω»‚É‚æ‚èA“K‹XA•ÏX‚·‚邱‚Ƃ͂ ‚è‚Ü‚·B«—ˆAŒ¤‹†ŽÒ‚¾‚¯‚łȂA—Õ°ˆã‚⌟¸‹ZŽt‚ð–ÚŽw‚µ‚Ä‚¢‚éŠw¶‚³‚ñ‚àŠ½Œ}’v‚µ‚Ü‚·BˆãŠw‰ÈˆÈŠO‚Ì•û‚àŠ½Œ}‚µ‚Ü‚·iŒ»Ý‚àŠˆ–ô’†‚Å‚·jB
ƒ‰ƒ{‚ÌŒ©Šw‚àŽžAŽó‚¯•t‚¯‚Ä‚¢‚Ü‚·Bƒ[ƒ‹‚ȂǂÅA‰“—¶‚È‚‚¨‹CŒy‚É‚²˜A—‚‚¾‚³‚¢B
------------------------------------------------------------------------------------------------------------------
y‚±‚ê‚܂ł̎å‚ÈŒ¤‹†¬‰Êz
i‚Pj”’ŒŒ•a×–E‚Ì‘B‹@˜‚Ì“Á«‚𖾂炩‚É‚·‚錟¸–@A‚»‚ê‚ɑ΂·‚镪Žq•W“IŽ¡—Öò‚ÌŠ´Žó«ŒŸ¸–@‚ÌŠJ”
@”’ŒŒ•a‚ÍA”’ŒŒ•a×–E‚Ì–³§ŒÀ‚Ì‘B‚Ƴ푢ŒŒ‹@\‚ÌáŠQ‚É‚æ‚èA‚»‚Ì•a‘Ô‚ªŒ`¬‚³‚ê‚éB”’ŒŒ•a×–E‚Ì‘B‚ÍA‚»‚Ì×–EW’c‚Ì’†‚Ì‚²‚”‚Ì”’ŒŒ•aвזE‚É‚æ‚Á‚Ĉێ‚³‚ê‚Ä‚¢‚éBŽ„‚½‚¿‚ÍA”’ŒŒ•aвזE‚̧ŒäƒƒJƒjƒYƒ€‚ð×–EE•ªŽqƒŒƒxƒ‹‚Å–¾‚ç‚©‚É‚·‚邱‚Ƃɂæ‚èAгŽÒ‚³‚ñ‚²‚Ƃ̔’ŒŒ•aвזE‚Ì“Á’¥‚𖾂炩‚É‚·‚錟¸–@‚ÆA‚»‚Ì•ªŽq•a‘Ԃɉž‚¶‚½Ž¡—Ö@A‚¨‚æ‚ÑA‚»‚ÌŽ¡—ÃŒø‰Ê‚ð—\‘ª‚·‚錟¸–@‚ðŠJ”‚·‚邱‚Æ‚ð–ÚŽw‚µ‚Ä‚¢‚éB
@‚í‚ê‚í‚ê‚ÍA”’ŒŒ•aвזE‚Ì‘B‹@\‚ðƒTƒCƒgƒJƒCƒ“‚Ìì—p‚Æ‚¢‚¤ŠÏ“_‚©‚猤‹†‚𑱂¯‚Ä‚«‚½B‹ï‘Ì“I‚É‚ÍAƒTƒCƒgƒJƒCƒ“‚Ì”’ŒŒ•a×–E”|—{Œn‚É‚¨‚¯‚鎩ŒÈ•¡»”\‚╪‰»‘B”\‚Ö‚Ìì—pA”’ŒŒ•a×–E‚É”Œ»‚·‚éƒTƒCƒgƒJƒCƒ“‚âƒTƒCƒgƒJƒCƒ“Žó—e‘̂̉ðÍAƒTƒCƒgƒJƒCƒ“Žó—e‘̂̃VƒOƒiƒ‹“`’BŒn‚̉ð͂Ȃǂł ‚éB
@Œ»Ý‚Í‘¢ŒŒŠ²×–E‚ÌŽ©ŒÈ•¡»‚Éd—v‚È–ðŠ„‚ðŽ‚ÂNotchƒVƒOƒiƒ‹‚ÌA”’ŒŒ•a×–E‚Ì‘B‚É‚¨‚¯‚é–ðŠ„‚ÉÅ“_‚𓖂ĂȤ‹†‚µ‚Ä‚¢‚éBNotch‚Æ‚ÍA‘¢ŒŒŠ²×–E•\–ʂɔŒ»µ‚Ä‚¢‚é’`”’‚Å‚ ‚éB‚í‚ê‚í‚ê‚Í¢ŠE‚Éæ‹ì‚¯‚ÄAгŽÒ”’ŒŒ•a×–E‚ÉNotch’`”’‚âNotchƒŠƒKƒ“ƒh’`”’‚ª”Œ»‚µ‚Ä‚¢‚邱‚Æ‚ð•ñ‚µANotchƒŠƒKƒ“ƒh”½‰ž«‚̃qƒg×–EŠ”‚ðŽ÷—§‚µ‚½B‚³‚ç‚É“–Œ¤‹†Žº‚Ì‘åŠw‰@¶‚炪A”’ŒŒ•a×–E‚Ì‘B‚╪‰»‚ɑ΂·‚éNotchƒŠƒKƒ“ƒh’`”’‚âNotch‘jŠQ–ò‚Ìì—p‚â‚»‚Ì•ªŽq‹@˜‚ÉŠÖ‚·‚é‹»–¡[‚¢”Œ©‚ð‚µA•ñ‚µ‚Ä‚«‚½BNotchƒVƒOƒiƒ‹‚̧Œä‚ÍAĶˆã—Â┒ŒŒ•a‚ɑ΂·‚镪Žq•W“IŽ¡—Âւ̉ž—p‚ªŠú‘Ò‚³‚ê‚Ä‚¨‚èA—Õ°‰ž—p‚ÉŒü‚¯‚ÄA‘“àŒ¤‹†‹@ŠÖ‚âŠé‹ÆŒ¤‹†•”–傯‚Ì‹¤“¯Œ¤‹†‚ài‚߂Ă¢‚éBŋ߂ÍANotchƒVƒOƒiƒ‹‚Æ“¯—l‚ÉŠ²×–E‚̧Œä‚Éd—v‚ÈWntƒVƒOƒiƒ‹AHedgehogƒVƒOƒiƒ‹AmTORƒVƒOƒiƒ‹AHIFƒVƒOƒiƒ‹‚Ȃǂɂ‚¢‚Ä‚àŒ¤‹†‚µ‚Ä‚¢‚éB
@
m“–Œ¤‹†Žº‚Ås‚È‚í‚ꂽAã‹L‚ÉŠÖ‚·‚éŋ߂̘_•¶n–ˆó@‘åŠw‰@¶(‚à‚µ‚‚͈ãŠw•”Šw¶)‚ª•M“ª’˜ŽÒ‚̘_•¶
@ Hypoxia
up-regulates HIF expression while suppressing cell growth and NOTCH
activity in leukaemia cells
–NOTCH
activation promotes glycosyltransferase expression in human myeloid leukemia
cells@
@ FOXP3 knockdown inhibits the proliferation
and reduces NOTCH1 expression of T cell acute lymphoblastic leukemia cells
–Effects
of MERTK inhibitors UNC569 and UNC1062 on the growth of acute myeloid leukaemia
cells.
–MYD88 Inhibitor ST2825 Suppresses
the Growth of Lymphoma and Leukaemia Cells.
–BMI1
Inhibitors Downregulate NOTCH Signalling and Suppress Proliferation of Acute
Leukemia Cells.
–Effect of EPH-ephrin signaling on the growth
of human leukemia cells.
–NOTCH Knockdown Affects the Proliferation and mTOR Signaling of Leukemia
Cells.
–Effects of the HIF1 Inhibitor, Echinomycin, on
Growth and NOTCH Signalling in Leukaemia.
–Comparative
effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in
leukemia cells.
–Effect of BMP4
on the growth and clonogenicity of human leukemia and lymphoma cells.
–Flow
cytometric analysis of Notch1 and Jagged1 expression in normal blood cells and
leukemia cells.
–Promotion of
the Self-renewal Capacity of Human Leukemia Cells by Sonic Hedgehog Protein.
–Effects of
Combination of Notch Inhibitor plus Hedgehog Inhibitor or Wnt Inhibitor on
Growth of Leukemia Cells.
–Gamma-secretase inhibitors induce erythroid differentiation in
erythroid leukemia cell lines.
–Effects of g-secretase inhibitors on the growth of leukemia cells.
–Cyclopamine and quercetin suppress the growth of leukemia and
lymphoma cells.
–Transition of cleaved Notch1 and gene expression changes in
myeloblastic leukemia cells stimulated with Notch ligands.
@ NFkB activation induced by Notch ligand stimulation in acute myeloid leukemia
cells.
–Promotion of the self-renewal capacity of
human acute leukemia cells by Wnt3A.
–Involvement of Notch
signaling in myelodysplastic syndrome.
–g-secretase inhibitors suppress the growth of leukemia and lymphoma
cells.
i‚QjŽîᇂÌV‚½‚Ȉâ“`ŽqŒŸ¸–@A”÷—ÊŽc‘¶Žîá‡×–E‚ÌŒŸo–@‚ÌŠJ”
@ŠàŽ¡—Â̖ڕW‚ÍAŽîá‡×–E‚ðªâ‚µŠ³ŽÒ‚ðŽ¡–ü‚É“±‚‚±‚Ƃɂ ‚éBŽíX‚Ì—LŒø‚ÈŽ¡—Â̌ã‚É‚àA”÷—ÊŽîá‡×–E‚ÌŽc‘¶‚âÄ”‚Ì–â‘肪Žc‚³‚ê‚Ä‚¢‚éB‚±‚Ì”÷—ÊŽîá‡×–E‚ÌŒŸo‚ÍA’ljÁŽ¡—Â̕K—v«‚Ì”»’f‚âAÄ”‚Ì‘Šú”Œ©‚É—L—p‚Å‚ ‚éB‚í‚ê‚í‚ê‚͈â“`ŽqŒŸ¸‚ð—p‚¢‚ÄA”÷—ÊŽîá‡×–E‚ð“KŠi‚ÉŒŸo‚·‚錟¸–@‚ÌŠJ”‚ÉŽæ‚è‘g‚ñ‚Å‚¢‚éB
m“–Œ¤‹†Žº‚Ìã‹L‚ÉŠÖ‚·‚éŋ߂̘_•¶n
–Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.
@ Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia
cells.
–Advantages of the quenching probe method
over other PCR-based methods for detection of the JAK2 V617F mutation.
@
Polymerase chain reaction detection of rearranged immunoglobulin heavy
chain DNA in plasma samples is useful in the diagnosis of B-cell lymphoma.
i‚Rj׋ÛEƒEƒCƒ‹ƒXŠ´õ‚ÆŽíX‚ÌŽ¾Š³‚Ƃ̊ւíè‚̉ðÍAŠ´õǂ̈â“`ŽqŒŸ¸–@
@‹ß”NAƒEƒCƒ‹ƒXŠ´õ‚ÆAŽíX‚ÌŽ¾Š³‚̔ǂâ•a‘ÔŒ`¬‚É‚¨‚¯‚é–ðŠ„‚Æ‚ÌŠÖ˜A‚ª·‚ñ‚ÉŒ¤‹†‚³‚ê‚Ä‚¢‚éB‚í‚ê‚í‚ê‚Í—Õ°ŒŸ‘Ì‚ð—p‚¢‚ÄAEBƒEƒCƒ‹ƒX‚âƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠ´õ‚ÆƒŠƒ“ƒp‘B«Ž¾Š³‚Ƃ̊֘A‚ÌŒ¤‹†‚ðs‚Á‚Ä‚¢‚éB‚Ü‚½AƒsƒƒŠ‹ÛŠ´õ‚ÆŽ©ŒÈ–Ɖu«Ž¾Š³‚̔ǂƂ̊֘A‚ɂ‚¢‚Ä‚à‰ðÍ‚µ‚Ä‚¢‚éB
m“–Œ¤‹†Žº‚Ìã‹L‚ÉŠÖ‚·‚éŋ߂̘_•¶n
@ Catheter-related bloodstream infection by Tsukamurella
inchonensis in an immunocompromised patient.
@
First report of sepsis caused by Rhodococcus corynebacterioides in a
patient with myelodysplastic syndrome.
@
Human herpesvirus 8 DNA in HIV-negative Japanese patients with
multicentric Castleman's disease and related diseases.
@
Resolution of refractory idiopathic thrombocytopenic purpura after
eradication of Helicobactor pyroli.
i‚SjÇ—á‚Ì×–E•ªŽq¶•¨Šw“I‰ðÍ
@Žîá‡«Ž¾Š³‚ð’†S‚Æ‚·‚é—Õ°Ç—á‚ɂ‚¢‚ÄA‚»‚ÌŽîá‡×–E‚Ì“Á«‚ðA×–E”|—{AõF‘̉ðÍADNAERNA‚Ì�ðÍA×–E•\–Ê‚¨‚æ‚Ñ×–E“à’`”’‚̉ð͂Ȃǂɂæ‚èÚׂɉðÍ‚µAÇ—á•ñ‚ðs‚Á‚Ä‚¢‚éB
m“–Œ¤‹†Žº‚Ìã‹L‚ÉŠÖ‚·‚éŋ߂̘_•¶n
@@A
case of gray platelet syndrome masked by immune thrombocytopenia at
presentation.
–Amplification of IGH/CCND1 fusion gene in a
primary plasma cell leukemia case.
@ An autopsy case of multicentric
Castleman's disease associated with interstitial nephritis and secondary AA
amyloidosis.
i‚Tj×–EŠ”‚ÌŽ÷—§
@—Õ°ŒŸ‘Ì‚©‚番—£‚µ‚½Žîá‡×–E‚ð”|—{‚µ‚ÄA‚±‚ê‚܂łSŽí—ނ̃qƒg”’ŒŒ•aEƒŠƒ“ƒpŽî×–EŠ”‚ðŽ÷—§‚µ‚½B‚±‚ê‚ç‚ÍA‚»‚ÌŽ¾Š³‚Ì×–Eƒ‚ƒfƒ‹‚Æ‚µ‚ÄŒ¤‹†‚É—p‚¢‚Ä‚¢‚éB
m“–Œ¤‹†Žº‚Ìã‹L‚ÉŠÖ‚·‚éŋ߂̘_•¶n
@ Establishment of a novel B-cell lymphoma
cell line with suppressed growth by gamma-secretase inhibitors.
@ A novel cell line derived from de novo acute
myeloblastic leukaemia with trilineage myelodysplasia which proliferates in
response to a Notch ligand, Delta-1 protein.
@
Establishment of a double Philadelphia chromosome-positive acute
lymphoblastic leukemia-derived cell line.
y“–Œ¤‹†Žº‚̃ƒ“ƒo[z2024”N‚SŒŽŒ»Ý
yã‹L‚ÌŒ¤‹†‚ð’S“–‚·‚鋳ˆõz
‹³Žö@@“Œ“c C“ñ
uŽt@@ˆÉ“¡
^ˆÈ
yÝÐ’†‚Ì‘åŠw‰@¶z
CŽm‰Û’ö@‚P–¼
yŽÀŒ±Žº‚Ì•—Œiz
y2012”N12ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ ‹ž“s:@‘Sˆõ‚Ì”•\‚ªI‚í‚èA“’—t—¿—‚̑ł¿ã‚°‰ï‚Éo”Iz
y2013”N12ŒŽ@ƒAƒƒŠƒJŒŒ‰tŠw‰ï @ ƒjƒ…[ƒI[ƒŠƒ“ƒYF Notchƒlƒ^‚âHIFƒlƒ^‚Ì”•\‚ªI‚í‚èAƒIƒCƒXƒ^[‚̃ŒƒXƒgƒ‰ƒ“‚Öz
y2014”N11ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ •Ÿ‰ªF Œû‰‰‚ªI‚í‚èA…‚½‚«—¿’à‚Öz
y2015”N11ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ Šò•ŒF –é’x‚‚È‚èA‰wƒrƒ‹‚Ì’èH‰®‚őł¿ã‚°‚ð‚µ‚½‚½‚ßAŽü‚è‚Ì–À˜f‚ɂȂé‚̂ŎÊ^‚ÍŽB‚ç‚È‚©‚Á‚½z
@‚È‚µ
y2016”N3ŒŽ@Asian Society for Clinical Pathology and Laboratory Medicine
Congress @ Taipeiz
y2016”N9ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ _ŒËF Œû‰‰‚ªI‚í‚èA_ŒË‹‚ðH‚×I‚í‚Á‚½‚Æ‚±‚ëz
y2016”N12ŒŽ@ƒAƒƒŠƒJŒŒ‰tŠw‰ï @ San DiegoF MYD88ƒlƒ^‚Ì”•\‚𖳎–I—¹z
y2017”N8ŒŽ@Experimental HematologyŠw‰ï @ ƒhƒCƒcEƒtƒ‰ƒ“ƒNƒtƒ‹ƒg‘åŠwz
y2017”N11ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ ‹ž“sFŒû‰‰‚ªI‚í‚èAŒü‚©‚¢‚̃vƒŠƒ“ƒXƒzƒeƒ‹‚Å‚¨’ƒz
y2018”N11ŒŽ@—Õ°ŒŸ¸ˆãŠw‰ï @ VhF¬‚ñ‚Å‚¢‚½‚̂ŎÊ^‚È‚µz
y2019”N6ŒŽ@ƒˆ[ƒƒbƒpŒŒ‰tŠw‰ï—ƒAƒ€ƒXƒeƒ‹ƒ_ƒ€:TYRO3ƒlƒ^‚̃|ƒXƒ^[”•\‚Ì€”õ’†z
y2020”N@COVID-19‚Ì‚½‚ßAŠw‰ï‚ÌŒ»’nŠJÂȂµz